Visionary Healthcare

Channel profile:

Frost & Sullivan GIL Webcast Series

Our Helthcare webcasts cover Connected Health, Life Sciences and Advanced Medical Technologies to help you to better understand buyer-seller dynamics as the healthcare system transitions to digital information, the pace at which new and innovative medical devices and systems are being adopted and getting embedded into the typical clinical pathway, both in mature and emerging markets, and enables you to bring clarity to pharmaceutical/biotechnology, in-vitro diagnostics and life science research tools market decisions and implementation tactics.

Subscribers (6,164)
The New Age of Regenerative Medicine – Why Stem Cell Therapy? Jane Andrews, Ph.D., senior consultant, Healthcare & Life Science Cell therapy is the fastest growing segment of regenerative medicine. Cell therapy is comprised of immune cell therapy and stem cell therapy, with stem cell therapy making up the largest part of this market; it is estimated that the global stem cell therapy market will reach $40 billion by 2020 and $180 billion by 2030.

Many factors determine the rate at which the stem cell therapy market advances. It is driven by the success of stem cell treatments in curing life-threatening diseases such as cancer, heart diseases and neuromuscular diseases in the world’s aging populations. In contrast, the stem cell market growth rate is hindered by manufacturing and regulatory concerns. For example, if only 20% of the 318 global late-stage clinical trials are approved for release on the market, there will not be enough stem cell therapy manufacturing facilities to produce the 64 resulting products. This is due, in part, to funding concerns, the high cost of build-out, as well as cGMP compliance, standardization of production processes, and ever changing industry regulations.
Read more >
Sep 22 2015 3:00 pm
UTC
60 mins
Attend
  • Date
  • Rating
  • Views
  • Cell therapy is the fastest growing segment of regenerative medicine. Cell therapy is comprised of immune cell therapy and stem cell therapy, with stem cell therapy making up the largest part of this market: it is estimated that the global stem cell therapy market will reach $40 billion by 2020 and $180 billion by 2030.

    Many factors determine the rate at which the stem cell therapy market advances. It is driven by the success of stem cell treatments in curing life-threatening diseases such as cancer, heart diseases and neuromuscular diseases in the worlds aging populations. In contrast, stem cell market growth rate is hindered by manufacturing and regulatory concerns. For example, if only 20% of the 318 global late stage clinical trials are approved for release on the market, there will not be enough stem cell therapy manufacturing facilities to produce the 64 resulting products. This is due, in part, to funding concerns, the high cost of build-out as well as cGMP compliance, standardization of production processes, and ever changing industry regulations.

    Join us as we discuss these and other key topics.
  • The Asia Pacific is the third largest pharmaceutical market in the world after North America and Europe, with generics being the major driver for the pharmaceutical industry in this region, aided by factors such as the aging population and impending expiry of patented drugs. It is a necessity for pharmaceutical companies to be aware of the key trends in the APAC generics market and maximise the market opportunities in order to remain relevant.

    In today’s rapidly evolving business landscape, pharmaceutical companies are also starting to realise the importance of the customer experience as a key differentiator. With a gradual shift from product to the customer, the pharmaceutical industry needs to keep up with other industries in terms of providing the perfect digital customer experience. A well-executed digital strategy is essential for today’s pharmaceutical companies to better connect with their clients.

    Join us as we discuss these and other key topics.
  • The healthcare industry is entangled in a transitory phase where therapeutics, products and services are sold into traditional care settings that are saturated and exhausted. Yet, the opportunities for new services and care, like ambulatory, mobile, and home care, lack the appropriate level of maturity to provide robust revenue streams.

    As a result, Frost & Sullivan’s experts are predicting a year full of big disruptions, transformations and innovations. What’s in store for pharmaceuticals, biotechnology, medical devices, medical imaging, mobile health, healthcare IT, etc.? This briefing will provide an in-depth discussion examining at what degree we can expect the impact to take hold and transpire over the upcoming year.

    Attend this webinar to discover:
    •Insightful analyst predictions and probative analysis of the global healthcare industry in 2015.
    •Key strategies and initiatives executed by companies and organizations to capture opportunities for solutions in health, wellness, and prevention.
    •Track the progress of key macro level industry trends and their projected milestones for 2015.
    •An interactive Q&A session with Frost & Sullivan’s senior industry thought leaders.
  • Public and private sector initiatives continue to transform the Healthcare industry in the Asia-Pacific - and their impact is likely to be seen in the coming months. For example, improving access to quality and affordable healthcare is a major goal of governments across the region, and a focus for reform efforts in many countries.

    Frost & Sullivan provides in-depth insights on how impending regulations, ethics and compliance reforms, emerging business and service models and industry partnerships will impact healthcare in the region

    Join us as we examine key trends for 2015 and beyond and discuss their impact on pharmaceuticals, medical devices, health technology, insurance, healthcare delivery and wellness across Asia-Pacific.
  • Given increasing healthcare consumerism and demand for round-the-clock healthcare delivery, hospitals and providers must upgrade their healthcare IT infrastructure to accommodate patient and provider needs. This briefing will investigate the changing technology landscape in hospitals globally and will specifically focus on how hospitals in North America and Europe are adopting health information systems (HIS).

    Attend this webinar to discover:

    ·Information technology systems in hospitals
    ·Drivers and restraints of HIS
    ·A technology and adoption roadmap of HIS
  • Telecommunication companies are increasingly seeking new revenue streams by exploring vertical markets like healthcare. Though traditional telecommunication services have achieved strong penetration in the healthcare industry, more sophisticated solutions are only now starting to generate sustainable returns and have a long way to go in terms of enabling a new-age healthcare system. While the industry presents promising opportunities, few telecommunication service providers have been able to establish successful business models in this space.
    Frost & Sullivan will present insights on critical factors that companies overlook while developing their healthcare strategy.

    Attend this webinar to discover:

    •Key success factors necessary for all telecommunication companies establishing a healthcare presence
    •Emerging business models that promise sustainable revenue for leading telecommunication companies in healthcare
  • Attend this webinar to discover:

    •Changes to healthcare delivery: hospitals of the future, aging in place, cost of care innovations
    •Role of the patient and consumer influence
    •Role of emerging regions as a consumer and competitor
    •Novel industry business models
    •Key disruptive technologies
  • Frost & Sullivan will provide an outlook for healthcare in 2014 with detailed insights on the regulatory challenges, investment trends, innovation temperature and emerging business models in the Asia-Pacific Healthcare market.
  • Attend this webinar to discover:

    • Insight into the sleep apneic industry
    • Drivers and restraints of the industry
    • Current trends and technology roadmap
  • Why You Should Attend:

    • Discover the issues involved in regulatory and payer acceptance of biosimilars in the US
    • Learn how biosimilars are forecast to penetrate the various biopharmaceutical segments and therapeutic areas
    • Understand the potential risks and rewards of this market
    • Gain insight into the competitive environment and the potential US market leaders
    • Identify the factors with the potential to impact the uptake of biosimilars

Embed in website or blog